0MH6 Stock Chart & Stats
€164.70
€1.60(1.01%)
At close: 4:00 PM EDT
€164.70
€1.60(1.01%)
Day’s Range― - ―
52-Week Range€113.20 - €176.60
Previous CloseN/A
Volume63.19K
Average Volume (3M)22.84K
Market Cap
€11.80B
Enterprise Value€12.99B
Total Cash (Recent Filing)€1.97B
Total Debt (Recent Filing)€963.20M
Price to Earnings (P/E)23.0
Beta0.94
Next Earnings
Feb 11, 2027EPS Estimate
7.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.20
Shares Outstanding83,814,530
10 Day Avg. Volume16,573
30 Day Avg. Volume22,839
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)2.29
Price to Sales (P/S)2.70
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€170.00Price Target Upside3.22% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)14.67
Revenue Forecast (FY)€4.54B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthSteady multi-year revenue expansion indicates continued demand for Ipsen’s specialty medicines and broad commercial reach. A stronger 2025 performance provides a durable base for funding clinical development, lifecycle management, and geographic growth over the coming quarters.
Healthy ProfitabilityIpsen remains meaningfully profitable despite recent margin pressure, with a roughly 30% EBITDA margin supporting investment in innovation and commercialization. This operating profitability gives the specialty portfolio resilience and preserves capacity to generate earnings as revenues expand.
Strong 2025 Free Cash FlowFree cash flow closely matching reported earnings is a positive quality-of-earnings signal and demonstrates strong cash conversion in 2025. This improves Ipsen’s ability to support research, partnerships, debt management, and shareholder returns without relying entirely on external funding.
Bears Say
Margin CompressionThe substantial decline in net margin shows that earnings are not expanding as efficiently as revenue. If this pressure persists, it could limit profit growth, reduce the cash available for pipeline investment, and weaken the operating leverage expected from continued top-line expansion.
Sharp Debt IncreaseIpsen still has a conservative debt-to-equity ratio, but the sharp year-over-year increase in total debt warrants attention. Higher obligations can reduce financial flexibility and increase the importance of sustained cash generation when funding development and other strategic priorities.
Volatile Cash ConversionThe strong 2025 cash-flow rebound is encouraging, but inconsistent conversion across prior years indicates variability in the timing and quality of cash generation. Such volatility can complicate budgeting, reduce confidence in recurring funding capacity, and constrain capital allocation during weaker periods.
Ipsen News
0MH6 FAQ
What was Ipsen’s price range in the past 12 months?
Ipsen lowest share price was €113.20 and its highest was €176.60 in the past 12 months.
What is Ipsen’s market cap?
Ipsen’s market cap is €11.80B.
When is Ipsen’s upcoming earnings report date?
Ipsen’s upcoming earnings report date is Feb 11, 2027 which is in 122 days.
How were Ipsen’s earnings last quarter?
Ipsen released its earnings results on Jul 30, 2026. The company reported €7.33 earnings per share for the quarter, beating the consensus estimate of €6.32 by €1.01.
Is Ipsen overvalued?
According to Wall Street analysts Ipsen’s price is currently Undervalued.
Does Ipsen pay dividends?
Ipsen does not currently pay dividends.
What is Ipsen’s EPS estimate?
Ipsen’s EPS estimate is 7.22.
How many shares outstanding does Ipsen have?
Ipsen has 83,814,530 shares outstanding.
What happened to Ipsen’s price movement after its last earnings report?
Ipsen reported an EPS of €7.33 in its last earnings report, beating expectations of €6.32. Following the earnings report the stock price went down -2.229%.
Which hedge fund is a major shareholder of Ipsen?
Currently, no hedge funds are holding shares in GB:0MH6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ipsen
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
0MH6 Stock 12 Month Forecast
Average Price Target
€170.00
▲(3.22% Upside)